Physician profile
Thomas Jack Shoemaker
NPI 1629335450
$277,969.52
in general payments reported to CMS, 2019-2025
11 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,001 · 2020: $38K · 2021: $42K · 2022: $53K · 2023: $50K · 2024: $39K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Consulting Fee: $7,450 · Honoraria: $6,950 · Food and Beverage: $3,622 · Travel and Lodging: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117,911.00 |
| Consulting Fee | $7,450.00 |
| Honoraria | $6,950.00 |
| Food and Beverage | $3,621.57 |
| Travel and Lodging | $1,015.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $124,733.70 | 2019-2025 | Tysabri, Vumerity |
| Emd Serono, INC. | $83,008.14 | 2020-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $21,817.04 | 2019-2025 | Ocrevus, Enspryng |
| Horizon Therapeutics Plc | $20,884.24 | 2021-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $20,196.44 | 2019-2023 | Soliris |
| Amgen INC. | $6,545.70 | 2024-2025 | Uplizna |
| Tg Therapeutics, INC. | $268.21 | 2025 | |
| Genzyme Corporation | $243.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $181.06 | 2022 | |
| Genentech, INC. | $79.90 | 2019 | |
| Celgene Corporation | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.